Full Text View
Tabular View
No Study Results Posted
Related Studies
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
This study has been completed.
Study NCT00460746   Information provided by Tibotec, Inc
First Received: April 13, 2007   Last Updated: April 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV
Interventions listed in this trial
TMC125, Darunavir; Ritonavir
Additional drug interventions recognized in this trial
Darunavir
Enfuvirtide
Protease Inhibitors
Reverse Transcriptase Inhibitors
Ritonavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
HIV Fusion Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services